These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 17300966)

  • 21. Structure of RNA aptamer for HIV Tat complexed with Tat-derived peptide.
    Matsugami A; Tamura Y; Kudo M; Uesugi S; Yamamoto R; Kumar P; Katahira M
    Nucleic Acids Symp Ser (Oxf); 2004; (48):111-2. PubMed ID: 17150503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of the solution conformations of unbound and Tat peptide-bound forms of HIV-1 TAR RNA.
    Long KS; Crothers DM
    Biochemistry; 1999 Aug; 38(31):10059-69. PubMed ID: 10433713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proximity of a Tat peptide to the HIV-1 TAR RNA loop region determined by site-specific photo-cross-linking.
    Wang Z; Huq I; Rana TM
    Bioconjug Chem; 1999; 10(3):512-9. PubMed ID: 10346885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Orientation and affinity of HIV-1 Tat fragments in Tat-TAR complex determined by fluorescence resonance energy transfer.
    Cao H; Tamilarasu N; Rana TM
    Bioconjug Chem; 2006; 17(2):352-8. PubMed ID: 16536465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro selection identifies key determinants for loop-loop interactions: RNA aptamers selective for the TAR RNA element of HIV-1.
    Ducongé F; Toulmé JJ
    RNA; 1999 Dec; 5(12):1605-14. PubMed ID: 10606271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring TAR-RNA aptamer loop-loop interaction by X-ray crystallography, UV spectroscopy and surface plasmon resonance.
    Lebars I; Legrand P; Aimé A; Pinaud N; Fribourg S; Di Primo C
    Nucleic Acids Res; 2008 Dec; 36(22):7146-56. PubMed ID: 18996893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LNA and alpha-L-LNA: towards therapeutic applications.
    Wengel J; Vester B; Lundberg LB; Douthwaite S; Sørensen MD; Babu BR; Gait MJ; Arzumanov A; Petersen M; Nielsen JT
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):601-4. PubMed ID: 14565236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rational and combinatorial strategies for designing oligonucleotides targeted to RNA structures.
    Toulmé JJ; Le Tinévez R; Boiziau C; Dausse E
    Nucleic Acids Symp Ser; 1997; (36):39-41. PubMed ID: 9478200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis, cellular uptake and HIV-1 Tat-dependent trans-activation inhibition activity of oligonucleotide analogues disulphide-conjugated to cell-penetrating peptides.
    Turner JJ; Arzumanov AA; Gait MJ
    Nucleic Acids Res; 2005; 33(1):27-42. PubMed ID: 15640444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The TAR hairpin of human immunodeficiency virus type 1 can be deleted when not required for Tat-mediated activation of transcription.
    Das AT; Harwig A; Vrolijk MM; Berkhout B
    J Virol; 2007 Jul; 81(14):7742-8. PubMed ID: 17494072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanistic studies of mini-TAR RNA/DNA annealing in the absence and presence of HIV-1 nucleocapsid protein.
    Vo MN; Barany G; Rouzina I; Musier-Forsyth K
    J Mol Biol; 2006 Oct; 363(1):244-61. PubMed ID: 16962137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tricyclo-DNA containing oligonucleotides as steric block inhibitors of human immunodeficiency virus type 1 tat-dependent trans-activation and HIV-1 infectivity.
    Ivanova G; Reigadas S; Ittig D; Arzumanov A; Andreola ML; Leumann C; Toulmé JJ; Gait MJ
    Oligonucleotides; 2007; 17(1):54-65. PubMed ID: 17461763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 TAR as anchoring site for optimized catalytic RNAs.
    Puerta-Fernandez E; Barroso-del Jesus A; Romero-López C; Berzal-Herranz A
    Biol Chem; 2003 Mar; 384(3):343-50. PubMed ID: 12715885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endogenous expression of an anti-TAR aptamer reduces HIV-1 replication.
    Kolb G; Reigadas S; Castanotto D; Faure A; Ventura M; Rossi JJ; Toulmé JJ
    RNA Biol; 2006 Oct; 3(4):150-6. PubMed ID: 17299271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Properties of an LNA-modified ricin RNA aptamer.
    Förster C; Zydek M; Rothkegel M; Wu Z; Gallin C; Geßner R; Lisdat F; Fürste JP
    Biochem Biophys Res Commun; 2012 Mar; 419(1):60-5. PubMed ID: 22326915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element.
    Vickers T; Baker BF; Cook PD; Zounes M; Buckheit RW; Germany J; Ecker DJ
    Nucleic Acids Res; 1991 Jun; 19(12):3359-68. PubMed ID: 2062653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular dynamics reveals the stabilizing role of loop closing residues in kissing interactions: comparison between TAR-TAR* and TAR-aptamer.
    Beaurain F; Di Primo C; Toulmé JJ; Laguerre M
    Nucleic Acids Res; 2003 Jul; 31(14):4275-84. PubMed ID: 12853646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins.
    Desfosses Y; Solis M; Sun Q; Grandvaux N; Van Lint C; Burny A; Gatignol A; Wainberg MA; Lin R; Hiscott J
    J Virol; 2005 Jul; 79(14):9180-91. PubMed ID: 15994812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liquid-crystal NMR structure of HIV TAR RNA bound to its SELEX RNA aptamer reveals the origins of the high stability of the complex.
    Van Melckebeke H; Devany M; Di Primo C; Beaurain F; Toulmé JJ; Bryce DL; Boisbouvier J
    Proc Natl Acad Sci U S A; 2008 Jul; 105(27):9210-5. PubMed ID: 18607001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surface plasmon resonance investigation of RNA aptamer-RNA ligand interactions.
    Di Primo C; Dausse E; Toulmé JJ
    Methods Mol Biol; 2011; 764():279-300. PubMed ID: 21748648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.